BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Priscilla K. Brastianos; Erin Twohy; Susan Geyer; Elizabeth R. Gerstner; Timothy J. Kaufmann; Shervin Tabrizi; Brian Kabat; Julia Thierauf; Michael W. Ruff; Daniela A. Bota; David A. Reardon; Adam L. Cohen; Macarena I. De La Fuente; Glenn J. Lesser; Jian Campian; Pankaj K. Agarwalla; Priya Kumthekar; Bhupinder Mann; Shivangi Vora; Michael Knopp; A. John Iafrate; William T. Curry; Daniel P. Cahill; Helen A. Shih; Paul D. Brown; Sandro Santagata; Fred G. Barker; Evanthia Galanis

doi:10.1056/NEJMoa2213329

Back

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Journal article

Peer reviewed

BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas

Priscilla K. Brastianos, Erin Twohy, Susan Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Shervin Tabrizi, Brian Kabat, Julia Thierauf, Michael W. Ruff, Daniela A. Bota, …

The New England journal of medicine, Vol.389(2), pp.118-126

2023-07-13

DOI: https://doi.org/10.1056/NEJMoa2213329

Appears in Miller School of Medicine - Latest Publications

Abstract

Brain Tumor

Treatments in Oncology

Hematology

Neurology

Neurosurgery

Oncology

Genetic analysis has shown the presence of activating BRAF mutations in 94% of papillary craniopharyngiomas. A phase 2 study showed partial response or better in 15 of 16 previously untreated patients.

Metrics

115 Record Views

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.164 Endocrinology & Metabolism; 1.164.646 Acromegaly
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: BRAF–MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas
Creators: Priscilla K. Brastianos - Dana-Farber Brigham Cancer Center
Erin Twohy - Mayo Clinic
Susan Geyer - Winneshiek Medical Center
Elizabeth R. Gerstner - Dana-Farber Brigham Cancer Center
Timothy J. Kaufmann - Mayo Clinic in Arizona
Shervin Tabrizi - Dana-Farber Brigham Cancer Center
Brian Kabat - Dana-Farber Brigham Cancer Center
Julia Thierauf - Dana-Farber Brigham Cancer Center
Michael W. Ruff - Dana-Farber Brigham Cancer Center
Daniela A. Bota - Dana-Farber Brigham Cancer Center
David A. Reardon - Dana-Farber Brigham Cancer Center
Adam L. Cohen - Dana-Farber Brigham Cancer Center
Macarena I. De La Fuente - University of Miami, UMMG Dept of Neurology - Neuro-Oncology Div
Glenn J. Lesser - Dana-Farber Brigham Cancer Center
Jian Campian - Dana-Farber Brigham Cancer Center
Pankaj K. Agarwalla - Dana-Farber Brigham Cancer Center
Priya Kumthekar - Mayo Clinic in Florida
Bhupinder Mann - Dana-Farber Brigham Cancer Center
Shivangi Vora - Dana-Farber Brigham Cancer Center
Michael Knopp - Dana-Farber Brigham Cancer Center
A. John Iafrate - Dana-Farber Brigham Cancer Center
William T. Curry - Harvard University
Daniel P. Cahill - Dana–Farber Cancer Institute
Helen A. Shih - Dana-Farber Brigham Cancer Center
Paul D. Brown - Mayo Clinic in Arizona
Sandro Santagata - Dana-Farber Brigham Cancer Center
Fred G. Barker - Dana-Farber Brigham Cancer Center
Evanthia Galanis - Mayo Clinic in Arizona
Publication Details: The New England journal of medicine, Vol.389(2), pp.118-126
Publisher: Massachusetts Medical Society
Academic Unit: UMMG Dept of Neurology - Neuro-Oncology Div; Miller School of Medicine; UMMG Department of Neurology
Language: English
Resource Type: Journal article
Record Identifier: 991031910491002976